Johnson & Johnson
NYSE:JNJ · New York Stock Exchange
-$4.59 today
Vol 18.74M · Avg 7.71M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
32.9%
avg 25.2%
ROIC
13.7%
avg 12.8%
ROA
13.5%
avg 10.5%
Analysis
ROE is currently the strongest return metric at 32.9% versus its period average of 25.2%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joaquin Duato | Chief Executive Officer & Chairman | $6.50M | — | 63 | $326,407.00 | 0.01% |
Jennifer L. Taubert | Executive Vice President & Worldwide Chairman of Innovative Medicine | $3.31M | — | 62 | $10,899.17 | <0.01% |
Joseph J. Wolk | Executive Vice President & Chief Financial Officer | $3.22M | — | 59 | $38,961.00 | <0.01% |
John C. Reed | Executive Vice President of Innovative Medicine and R&D | $3.17M | — | 68 | $35,913.00 | <0.01% |
Timothy Schmid | Executive Vice President & Worldwide Chairman of MedTech | $2.54M | — | 56 | $25,447.00 | <0.01% |
Kristen Blair Mulholland | Executive Vice President & Chief Human Resources Officer | $2.15M | — | 59 | $20,322.00 | <0.01% |
Darren Snellgrove | Vice President of Investor Relations | — | — | — | — | — |
Dirk Brinckman | Chief Compliance Officer | — | — | — | — | — |
Guy J. Lebeau | Group Chairman of MD&D Business - EMEA | — | — | — | — | — |
Robert J. Decker Jr. | Controller & Chief Accounting Officer | — | — | 53 | $23,682.00 | <0.01% |
James Swanson | Executive Vice President & Chief Information Officer | — | — | 60 | $0.00 | <0.01% |
Elizabeth Forminard | Executive Vice President & Chief Legal Officer | — | — | 55 | $27,076.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
15
$55.49M
Net Sentiment
$55.49M
Net selling
Most Active
Wolk Joseph J
4 transactions
1–10 of 15
Analysis
Insiders reported 0 buys worth $0.00 and 15 sells worth $55.49M over the last 12 months. That adds up to net selling of $55.49M. Wolk Joseph J was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +12.4% | +8.0% (15yr)2 analysts |
| Revenue | N/A | N/A | +1.4% | +4.3% (15yr)15 analysts |
| Net Income | N/A | N/A | +12.4% | +7.0% (15yr)15 analysts |
| EBIT | N/A | N/A | +2.4% | +3.9% (15yr)15 analysts |
Analysis
Recent growth has been strongest in Net Income at +12.4% over three years. Forward estimates point to EPS at +8.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
AbbVie Inc.
NYSE:ABBV
$382.93B
UnitedHealth Group Incorporated
NYSE:UNH
$366.17B
Merck & Co., Inc.
NYSE:MRK
$282.20B
Novartis AG
NYSE:NVS
$281.84B
AstraZeneca PLC
NYSE:AZN
$271.37B
Novo Nordisk A/S
NYSE:NVO
$191.46B
Amgen Inc.
NASDAQ:AMGN
$180.95B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.72B
Pfizer Inc.
NYSE:PFE
$143.97B
Sanofi
NASDAQ:SNY
$101.57B
Who manages JNJ?
Johnson & Johnson (JNJ) lists 12 active executives. The top listed executive is Darren Snellgrove, Vice President of Investor Relations.
Are JNJ insiders buying or selling?
Recent insider activity shows net buying of $27.22M.
Explore More
Continue the stock analysis
Jump to another research area for this company.